Biopharmaceutical characteristics of a new propranolol/hydrochlorothiazide tablet combination.
Experiments have been carried out in dogs and man to determine the effect of hydrochlorothiazide (HCT) on the pharmacokinetics of propranolol and to evaluate the bioavailability of two dosage forms containing both propranolol and HCT (40/25 and 80/25 mg, respectively). In adult male beagles, 50 mg of HCT had no apparent effect on AUC, Cmax, Tmax, and T1/2 of propranolol administered concurrently. In man, INDERIDE (40/25 mg) and INDERIDE (80/25 mg) were shown to be similar in bioavailability to the reference formulations, i.e. the same amount of drugs administered as the separate tablets of INDERAL plus HYDRODIURIL.
D000293:Adolescent; D000328:Adult; D000818:Animals; D001682:Biological Availability; D004285:Dogs; D004338:Drug Combinations / Q000378:metabolism; D006801:Humans; D006852:Hydrochlorothiazide / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D011433:Propranolol / Q000378:metabolism*; D013045:Species Specificity; D013607:Tablets
D004338:Drug Combinations; D013607:Tablets; D006852:Hydrochlorothiazide; C034439:inderide; D011433:Propranolol